USP General Chapter <797> — Pharmaceutical Compounding for Sterile Preparations

Citation

United States Pharmacopeia, General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. Currently effective revision became official November 1, 2023. USP <797> is enforceable through state pharmacy board adoption, FDA inspection of registered outsourcing facilities, and accrediting body standards. USP itself does not enforce; enforcement flows through state and federal regulators that adopt USP standards.

What It Says (Operative Provisions Relevant to Pest Management)

USP <797> establishes environmental requirements for areas where sterile pharmaceutical preparations are compounded. While the chapter does not contain pest-specific language, its environmental cleanliness requirements have direct implications for pest exclusion and pest management in pharmacy compounding areas.

Cleanroom classification requirements:

Sterile compounding must occur in classified environments meeting ISO Class 5, 7, or 8 air cleanliness standards depending on the compounding category. ISO Class 5 (the cleanest classification) permits no more than 3,520 particles ≥0.5 micrometers per cubic meter of air. Any pest activity — including dead insects, insect fragments, or rodent droppings — constitutes particulate contamination incompatible with ISO classification maintenance.

Surface and facility design requirements:

USP <797> requires surfaces in compounding areas to be smooth, impervious, free of cracks and crevices, and non-shedding. Floor-to-ceiling joints must be sealed. Junctions between walls, floors, and ceilings must be coved. These design requirements simultaneously serve sterile compounding integrity and pest exclusion — eliminating harborage areas for insects and providing surfaces that can be effectively cleaned and inspected.

Environmental monitoring requirements:

Compounding facilities must conduct routine environmental monitoring including air sampling, surface sampling, and personnel monitoring. The presence of pest activity or pest-associated microbial contamination during environmental monitoring constitutes a critical deviation requiring investigation, corrective action, and potentially production interruption.

Pesticide application restrictions:

USP <797> does not explicitly address pesticide application in compounding areas. However, the chapter’s requirement that no extraneous materials, residues, or contaminants enter sterile compounding spaces creates substantial operational restrictions on pesticide application. Standard healthcare IPM practice in compounding areas defaults to physical exclusion, sanitation, and mechanical controls — with chemical controls used only outside compounding spaces or during scheduled facility shutdowns with full environmental restoration before compounding resumes.

What It Means in Plain Language

USP <797> is the federal standard of care for sterile pharmaceutical compounding in the United States. Its environmental requirements make pest management in pharmacy compounding areas a critical infection prevention and patient safety issue — not because the chapter addresses pests directly, but because pest activity is incompatible with the air, surface, and personnel cleanliness standards the chapter requires.

The practical implication for pest management programs serving pharmacy compounding areas:

1. Pesticide application in classified compounding spaces is essentially prohibited by the chapter’s environmental restrictions. Pest management in compounding areas must rely on physical exclusion (sealing, screening, secondary containment), sanitation (waste management, food restriction in adjacent areas), and mechanical controls (traps placed outside classified spaces).
2. Pest activity in compounding areas is a critical event. A single dead insect on a sterile preparation surface, a rodent dropping found during environmental monitoring, or evidence of pest activity in the compounding area documentation triggers investigation, corrective action, and potentially compounding suspension under USP <797> deviation management protocols.
3. Pest management must be coordinated with the Designated Person (DP). USP <797> requires each compounding facility to designate a person responsible for compounding operations. Pest management activities affecting compounding spaces must be coordinated through the DP. Service in compounding areas is not a routine pest management visit — it is a regulated activity affecting sterile compounding integrity.

Who It Applies To

USP <797> applies to:

• Hospital pharmacies performing sterile compounding (the majority of acute-care hospitals)
• Health-system outpatient pharmacies performing sterile compounding
• Long-term care facility pharmacies performing sterile compounding
• Standalone compounding pharmacies registered with the FDA or state pharmacy boards
• Ambulatory surgery center pharmacies performing sterile compounding

Enforcement occurs through:

• State pharmacy board inspections (the primary enforcement channel)
• FDA inspection of outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act
• Joint Commission and DNV-GL accreditation standards (which reference USP <797> as the standard of care for sterile compounding)
• CMS Conditions of Participation for hospitals (which reference USP <797> by inference through infection prevention requirements)

Documentation Evidence Required

For pest management documentation supporting USP <797> compliance in pharmacy compounding areas:

• Pest management plan addressing compounding areas specifically with documented coordination with the Designated Person
• Service records demonstrating non-chemical intervention priority in compounding spaces — inspection, exclusion, sanitation, and mechanical controls documented
• Pesticide application records for any chemical interventions with explicit documentation of containment, environmental restoration, and DP authorization
• Environmental monitoring coordination showing that pest management activities are timed and conducted in a manner that does not compromise environmental monitoring schedules
• Deviation response protocol documenting how pest activity findings in compounding areas trigger investigation and corrective action

How Surveyors Evaluate It

State pharmacy board inspectors evaluate compounding facilities directly against USP <797>. Joint Commission and DNV-GL surveyors evaluate hospital pharmacies under both their accreditation standards and USP <797> as the underlying standard of care.

Common pest-related findings during USP <797> evaluation:

• Evidence of pest activity in or adjacent to compounding areas (dead insects, droppings, harborage)
• Inadequate physical exclusion at entry points to compounding spaces (gaps under doors, unsealed penetrations, ineffective screens)
• Pest management activities in compounding areas conducted without DP coordination
• Pesticide residues or evidence of pesticide application without environmental restoration documentation
• Pest management documentation that does not distinguish compounding-area service from general facility service

Confidence Notes

MEDIUM confidence. USP General Chapter <797> verbatim text is paywalled in the USP-NF compendia (subscription-only). Operational requirements summarized on this page are derived from publicly available USP FAQ documents, state pharmacy board adoption materials, accrediting body summaries, and the USP <797> revision public comment record. Effective date (November 1, 2023) and chapter title verified from USP public metadata. Verbatim quotation of <797> requirements requires institutional USP-NF access.

Related Killed Claims

• “USP <797> explicitly prohibits pesticide application in classified compounding areas.” Partially disconfirmed. USP <797> does not contain an explicit prohibition on pesticide application. However, the chapter’s environmental cleanliness requirements create substantial practical restrictions that result in operational equivalence to prohibition in most compounding facilities.
• “USP <797> requires pharmacy compounding facilities to contract with Board Certified Entomologists.” Disconfirmed. USP <797> does not address pest management credentialing. The BCE credential is the highest-rigor available answer to compounding-area pest management complexity, but USP <797> itself does not require any specific credential.

Related Authorities

• USP General Chapter <800> — Hazardous Drugs — companion chapter addressing hazardous drug handling, with overlapping environmental requirements
• OSHA Hazard Communication Standard — pesticide SDS requirements applicable in pharmacy compounding contexts
• CDC HICPAC Section E.V. — healthcare facility pest management standards referenced as standard of care by pharmacy accreditation